No Data
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.
CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides
Piper Sandler Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $310
Amgen Is Maintained at Overweight by Piper Sandler
Analyst Expectations For Amgen's Future
Amgen Analyst Ratings
